Regeneron Faces Securities Lawsuit Over Failed Melanoma Trial

The litigation, filed by Robbins LLP, concerns investors who purchased Regeneron securities between August 1, 2025, and May 15, 2026. The complaint alleges that the pharmaceutical firm misled shareholders regarding the viability of its Fianlimab-Libtayo therapy, a monoclonal antibody treatment intended for patients with advanced melanoma. According to the court filings, the company failed to disclose that the study’s statistical assumptions were flawed and that the treatment was unlikely to achieve its primary endpoint of progression-free survival.

Financial consequences for shareholders intensified following two major disclosures. On April 29, 2026, Regeneron announced modifications to the study's patient analysis criteria, triggering a 6.2% drop in the company’s stock price. The situation deteriorated further on May 15, 2026, when the company confirmed that the trial had officially failed to meet its primary efficacy target. This announcement resulted in an additional 9.8% decline in value by May 18. The lawsuit seeks to recover damages for investors, arguing that these omissions caused shares to trade at artificially inflated prices throughout the specified class period.